Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8883158 Compositions and methods for antibodies targeting complement protein C5

Patent 8883158 was granted and assigned to Novartis on November, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novartis

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

88831580

Patent Inventor Names

Beate Diefenbach-Streiber0

Adina Eberth0

Braydon Charles Guild0

Igor Splawski0

Michael Roguska0

Yong-In Kim0

Date of Patent

November 11, 2014

Patent Application Number

135575620

Date Filed

July 25, 2012

Patent Citations Received

‌

US Patent 12128101 Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)

‌

US Patent 12076319 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

‌

US Patent 11780912 Composition for prophylaxis or treatment of IL-8 related diseases

‌

US Patent 12006307 Pharmaceutical compounds for treatment of medical disorders

‌

US Patent 12084516 Anti-C5 antibody combinations and uses thereof

‌

US Patent 11708351 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Patent Primary Examiner

‌

Lynn Bristol

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8883158 Compositions and methods for antibodies targeting complement protein C5

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API